Zoetis Appoints William F. Doyle to Board of Directors
February 04 2015 - 8:30AM
Business Wire
Zoetis Inc. (NYSE:ZTS), the world’s leading animal health
company, today announced that its Board of Directors has appointed
William F. Doyle, a Member of Pershing Square Capital Management’s
Investment Team, to the company’s Board of Directors, effective
February 3. With the addition of Mr. Doyle, the Zoetis Board will
expand to 10 directors. Zoetis and Pershing Square reached an
agreement providing for Mr. Doyle’s election as well as the
election in the future of an additional independent director
mutually acceptable to Zoetis and Pershing Square.
“We welcome Bill to the Zoetis Board,” said Zoetis Chief
Executive Officer Juan Ramón Alaix. “He brings significant
expertise and relevant industry and operational experience to
Zoetis and I am confident he will provide valuable insight and
perspectives as we continue to enhance our position as the world
leader in animal health.”
“As the industry leader in the animal health market, Zoetis is
an exceptional company with a diverse product portfolio and great
long-term value creation potential,” said William F. Doyle. “I look
forward to working constructively with Juan Ramón, Zoetis
management and the Board to deliver value for all shareholders over
the long-term.”
Mr. Doyle has more than 20 years of experience in the healthcare
industry. He is an Investment Team member at Pershing Square
Capital Management, L.P. He is also the Co-Founder and Managing
Partner at WFD Ventures LLC, which has provided equity financing
and industry expertise to medical device, pharmaceutical and
healthcare technology companies since 2003. From 1995 to 1999, he
served as an executive at Johnson & Johnson. Previously, Mr.
Doyle worked as a consultant with McKinsey & Company in its
global healthcare practice.
Mr. Doyle will serve on the Corporate Governance Committee.
Pursuant to the agreement with Zoetis, Pershing Square and
Sachem Head have agreed to certain customary standstill
provisions.
About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company,
dedicated to supporting its customers and their businesses.
Building on more than 60 years of experience in animal health,
Zoetis discovers, develops, manufactures and markets veterinary
vaccines and medicines, complemented by diagnostic products and
genetic tests and supported by a range of services. In 2013, the
company generated annual revenue of $4.6 billion. With
approximately 9,800 employees worldwide at the beginning of 2014,
Zoetis has a local presence in approximately 70 countries,
including 27 manufacturing facilities in 10 countries. Its products
serve veterinarians, livestock producers and people who raise and
care for farm and companion animals in 120 countries. For
more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to business plans or
prospects, future operating or financial performance, expectations
regarding products, future use of cash and dividend payments, and
other future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to
risks and uncertainties. If one or more of these risks or
uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ
materially from those contemplated by a forward-looking statement.
Forward-looking statements speak only as of the date on which they
are made. Zoetis expressly disclaims any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2013, including in the sections thereof captioned
“Forward-Looking Information and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
Zoetis Inc.Media Contacts:Bill
Price, 1-973-443-2742 (o)william.price@zoetis.comorElinore White,
1-973-443-2835 (o)elinore.y.white@zoetis.comorInvestor Contact:John O'Connor, 1-973-822-7088
(o)john.oconnor@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024